Historically, optic nerve involvement has been excluded from MS diagnostic criteria, but its inclusion in the new iteration is expected to significantly accelerate time to diagnosis. Medscape Medical News
Category: News
20/20 Onsite Expands Mobile Vision Fleet, Strengthening Nationwide Reach and Clinical Trial Support Capacity
BOSTON–(BUSINESS WIRE)–20/20 Onsite, the leading provider of point-of-need ophthalmic services for clinical trials, announces the deployment of its latest mobile vision clinic, bringing its fleet to 16 units, including a mix of mobile clinics, pods, …
New Guidelines Shift Diabetes Care Toward Behavior
The recommendations focus on helping patients implement lifestyle changes. Medscape Medical News
Rare Yet Alarming: US Study Maps Syphilitic Uveitis Trends
Both the incidence and prevalence of syphilitic uveitis increased in the United States from 2013 to 2024, with low vision and blindness being the most common ocular complications. Medscape Medical News
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
NASHVILLE, Tenn. & TAIPEI, Taiwan–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby …
Virginia G. Piper Charitable Trust Names Laura Smith as Director of Eyes On Learning
PHOENIX–(BUSINESS WIRE)– #Arizona–Virginia G. Piper Charitable Trust has appointed Laura Smith as the new director of Eyes On Learning, a coalition of state, local, and national organizations dedicated to improving the vision health of Arizona’s chi…
Virginia G. Piper Charitable Trust Names Laura Smith as Director of Eyes On Learning
PHOENIX–(BUSINESS WIRE)– #Arizona–Virginia G. Piper Charitable Trust has appointed Laura Smith as the new director of Eyes On Learning, a coalition of state, local, and national organizations dedicated to improving the vision health of Arizona’s chi…
Samenvatting: Biocytogen en Nanjing Chia Tai Tianqing kondigen IND-goedkeuring aan in China voor het gezamenlijk ontwikkelde anti-IGF-1R antilichaam NTB003 (BCG009)
BEIJING & NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) en Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (“NJCTTQ”) hebben bekendgemaakt dat voor hun gezamenlijk ontwikkelde injecteerbar…
Biocytogen et Nanjing Chia Tai Tianqing annoncent l’autorisation IND en Chine pour l’anticorps anti-IGF-1R NTB003 (BCG009) développé conjointement
PÉKIN et NANJING, Chine–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Pékin) Co., Ltd. (« Biocytogen », HKEX : 02315) et Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (« NJCTTQ ») ont annoncé que le NTB003 (anciennement BCG009), un candidat médica…
Resumen: Biocytogen y Nanjing Chia Tai Tianqing anuncian aprobación IND en China para el anticuerpo NTB003 (BCG009) desarrollado conjuntamente contra el IGF-1R
BEIJING y NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Pekín) Co. Ltd. (“Biocytogen”, HKEX: 02315) y Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (“NJCTTQ”) anunciaron que NTB003 (ex BCG009), un candidato a fármaco inyectable desar…
Riassunto: Biocytogen e Nanjing Chia Tai Tianqing annunciano l'approvazione IND in Cina per l'anticorpo anti-IGF-1R NTB003 (BCG009) sviluppato congiuntamente
BEIJING e NANJING, Cina–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) e Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) hanno annunciato che NTB003 (formerly BCG009), un farmaco candidato ini…
Biocytogen und Nanjing Chia Tai Tianqing geben IND-Zulassung in China für gemeinsam entwickelten Anti-IGF-1R-Antikörper NTB003 (BCG009) bekannt
BEIJING und NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. („Biocytogen“, HKEX: 02315) und Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. („NJCTTQ“) melden, dass NTB003 (zuvor BCG009), ein gemeinsam entwickelter, in…
GLP-1 RAs Linked to Doubled Risk for Macular Degeneration
Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for neovascular age-related macular degeneration in a large Canadian study. Medscape Medical News
Long-Term Exposure to Air Pollution Can Double Glaucoma Risk
Long-term exposure to air pollution increases the risk for primary open-angle glaucoma by up to 108%, a nationwide cohort study of over half a million individuals in Taiwan shows. Medscape Medical News
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…
Eye Health America Expands in Northeast Florida with the Addition of Schneider Eye & Wellness Center in Jacksonville Beach
JACKSONVILLE BEACH, Fla.–(BUSINESS WIRE)– #EyeCare–Eye Health America (EHA), a leading integrated eye care platform in the Southeastern United States, is proud to announce its newest partnership with Schneider Eye & Wellness Center, a respected …
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia
LONDON & SEATTLE–(BUSINESS WIRE)– #BRIMOCHOL–Tenpoint Therapeutics Ltd. announces FDA acceptance of New Drug Application for BRIMOCHOL™ PF for the treatment of presbyopia
Inexpensive HIV Med Improves Vision in Diabetic Eye Disease
An initial trial suggests lamivudine, an inexpensive oral drug for treating HIV, can improve vision in patients with diabetic macular edema more effectively and affordably than current therapies. Medscape Medical News
Warby Parker Announces Participation in the Baird Global Consumer, Technology & Services Conference
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Baird Global Consumer, Technology & Services Confe…
Irritant Contact Dermatitis
The patient’s medical history was significant for mild atopic dermatitis, well-controlled with triamcinolone ointment used intermittently, and a background of ichthyosis vulgaris. Medscape Dermatology